Clinical trials: Obesity in Diabetes
Obesity, Diabetes
Metabolic Parameters 3 Months, 9 Months, and 2 Years After Bariatric Surgery
An original cohort of 43 patients were recruited for analysis of anthropometrics, metabolic profile, skeletal muscle biopsy, echocardiogram at baseline, 3 months and 9 months post bariatric surgery.
- Conditions
- Obesity, Diabetes, Heart Failure, Insulin Resistance
- Trial name
- NCT00178633
- Testing
- Bariatric surgery
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- The University of Texas Health Science Center, Houston
Diabetes, Obesity
A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling
The purpose of this study is to determine whether a lipid infusion can up-regulate toll-like receptor 4 (TLR4) signaling in human subjects
- Trial name
- NCT01740817
- Testing
- Intralipid 20%, Saline
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Obese, Diabetes Mellitus, Type 2
Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects
The investigators will recruit obese subjects with pre-diabetes or type 2 diabetes for the proposed clinical study for 5 visits.
- Trial name
- NCT03991299
- Testing
- Botox 200 UNT Injection
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt University Medical Center
Obesity, Overweight
MOVE OUT: A Partnership With Veterans Groups to Enhance Weight Management in the Veterans Health Administration (VHA)
Obesity has been linked to several serious medical conditions, including high blood pressure, diabetes, and poor cholesterol levels.
- Conditions
- Obesity, Overweight, Hypertension, Diabetes Mellitus
- Trial name
- NCT01339390
- Testing
- MOVE OUT, MOVE!
- Where
- United States
- Volunteers
- 3,169 people
- Sponsor
- VA Office of Research and Development
Fatty Liver, Non-Alcoholic Steatohepatitis
A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH
This is a multicenter, Phase IIb, randomized, double blind, placebo-controlled study designed to evaluate the efficacy and safety of two Aramchol doses in subjects that are 18 to 75 years of age, with Non-Alcoholic…
- Conditions
- Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
- Trial name
- Aramchol_005 (NCT02279524)
- Testing
- Aramchol
- Where
- 78 sites in United States, Chile and 9 more
- Volunteers
- 247 people
- Sponsor
- Galmed Research and Development, Ltd.
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.
- Trial name
- SURMOUNT-3 (NCT04657016)
- Testing
- Tirzepatide
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 579 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company
Diabetes
Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects
To investigate whether the daily glucose profiles as assessed by continuous glucose monitoring for 1 week of normal weight and obese individuals relate to hunger levels and food intake.
- Trial name
- NCT02673203
- Testing
- Continuous Glucose Monitoring System (CGMS), Food log
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Yale University
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Overweight, Obese
A Study of CT-868 in Type 1 Diabetes Mellitus
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo.
- Conditions
- Overweight, Obese, Type 1 Diabetes Mellitus
- Trial name
- NCT06062069
- Testing
- CT-868, CT-868 Pen Injector
- Where
- 22 sites in United States
- Volunteers
- 111 people
- Sponsor
- Carmot Therapeutics, Inc.
Obesity & Overweight, Diabetes Mellitus Type 2
Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes
This study will examine whether the type of diabetes treatment used before cancer diagnosis is associated with survival and serious complications after obesity-associated cancer in adults with obesity and type 2 diabetes.
- Conditions
- Obesity & Overweight, Diabetes Mellitus Type 2, Neoplasms
- Trial name
- NCT07513259
- Where
- Taiwan
- Volunteers
- 203,424 people
- Sponsor
- Chung Shan Medical University
Hypogonadism
Testosterone Replacement in Men With Diabetes and Obesity
The purpose of this study is to examine the effect of having testosterone deficiency in men with diabetes and with obesity. The study will also evaluate the effect of testosterone therapy.
- Trial name
- NCT01127659
- Testing
- testosterone
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- University at Buffalo
Diabetes Mellitus, Obesity
Exercise to Reduce Obesity in Spinal Cord Injury
The purpose of this proposal was to evaluate and compare the health benefits of using upper extremity exercise versus functional electrical stimulation for lower extremity exercise.
- Conditions
- Diabetes Mellitus, Obesity, Paraplegia, Quadriplegia
- Trial name
- NCT00270855
- Testing
- Arm Crank Ergometry, FES Cycle Ergometer
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- VA Office of Research and Development
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and…
- Conditions
- Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT01234649
- Testing
- Metformin XR plus liraglutide
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Woman's
Type 2 Diabetes
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes
This is a Phase 2a study designed to assess the safety and tolerability of MEDI0382 titrated up to a dose level of 100, 200 or 300 µg from 50 µg vs Placebo across 48 days in Japanese subjects.
- Trial name
- NCT03645421
- Testing
- MEDI0382 100 μg, MEDI0382 200 μg, MEDI0382 300 μg
- Where
- 5 sites in Japan
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Cardiovascular Risk Factor, Cardiovascular Diseases
Substituting Sitting With Standing and Walking in Free-living Conditions Improves Daily Glucose Profile in South Asians
The purpose of this study is to investigate the effects of substituting sitting under free-living conditions in South Asian adults with overweight and obesity on continuous glucose profiles.
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Diabetes, Type 2 Diabetes
- Trial name
- NCT04645875
- Testing
- SIT regimen, SITless regimen
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Bedfordshire
Glucose Intolerance, Overweight and Obesity
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus.
- Conditions
- Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
- Trial name
- NCT04387201
- Testing
- Cyanocobalamin, Dulaglutide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Health Science Center, Houston
Diabetes Mellitus, Endocrine System Diseases
Soluble Epoxide Hydrolase Inhibition and Insulin Resistance
The purpose of this study is to test how soluble epoxide hydrolase (sEH) inhibition with GSK2256294 affects tissue sEH activity and insulin sensitivity.
- Conditions
- Diabetes Mellitus, Endocrine System Diseases, Glucose Metabolism Disorders, PreDiabetes
- Trial name
- NCT03486223
- Testing
- GSK2256294
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center